Brii Biosciences, a Durham biotechnology company with global headquarters in China, plans to buy the intellectual property and other remaining assets of a defunct company’s drug candidate for treating ...

The funding signals a fresh chapter for the clinical-stage biotech company, which focuses on degenerative musculoskeletal conditions. Durham’s Tavros Therapeutics sold to subsidiary of German giant ...

It looks like you're using an old browser. To access all of the content on Yr, we recommend that you update your browser. It looks like JavaScript is disabled in your browser. To access all the ...